Your session is about to expire
← Back to Search
Smoking Cessation Program for Cancer
Study Summary
This trial looks at whether an enhanced tobacco intervention protocol (ETIP) is better than standard treatment at helping people with head and neck or lung cancer to stop smoking cigarettes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a known allergy or severe skin reaction to NRT.I am not currently experiencing uncontrolled psychiatric illness nor am I on psychiatric medications.I haven't had major surgery, serious fractures, or heart issues in the last 6 weeks.I have smoked more than 100 cigarettes in my life and have smoked in the last 30 days.I recently had a heart attack or have serious heart rhythm problems or chest pain.I cannot swallow pills due to a severe condition.I am able to understand and make decisions about my health care.I am currently taking anti-depressants.I can read and speak English fluently.I am open to talking about changing my smoking habits.I am fluent in English.You are allergic to bupropion or varenicline, or have had severe skin reactions like Steven's Johnson syndrome.I haven't used nicotine or tobacco products for the required time before and after my surgery.I recently stopped using alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.I do not have a condition that increases my risk of seizures, such as a severe brain injury or eating disorder.I am a new patient at TJUH or Methodist with suspected or newly diagnosed head, neck, or lung cancer.
- Group 1: Arm I (ETIP)
- Group 2: Arm II SOC
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What conditions is Varenicline typically utilized to treat?
"Varenicline is most commonly prescribed to address Attention Deficit Hyperactivity Disorder (ADHD), but has also been used with success in treating Seasonal Affective Disorder, smoking cessation and nicotine addiction."
Are there any available openings for participants in this research endeavor?
"According to the records held on clinicaltrials.gov, this research project is actively looking for subjects and has been since August 19th 2020. The most recent update was issued on September 14th 2022."
How many participants have been accepted into this clinical trial thus far?
"Affirmative. Clinicaltrials.gov reveals this medical investigation is searching for participants; it was initially posted on August 19th 2020 and the most recent update occurred on September 14th 2022. The clinical trial requires 40 patients across two locations to be enrolled."
What other experiments have been undertaken to evaluate Varenicline?
"Currently, 113 studies on Varenicline are ongoing - 17 of which are Phase 3 trials. Most of these experiments take place in Charleston, South carolina although there are 530 sites worldwide conducting related research."
Share this study with friends
Copy Link
Messenger